Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide

We previously conducted a randomized phase II trial of OCV-501, a WT1 peptide presented by helper T cells, in elderly AML (acute myeloid leukemia) patients in first remission, indicating no difference in 2-year disease-free survival (DSF) between the OCV-501 and placebo groups. Here, we analyzed 5-y...

Descripción completa

Detalles Bibliográficos
Autores principales: Naoe, Tomoki, Saito, Akiko, Hosono, Nahoko, Kasahara, Senji, Muto, Hideharu, Hatano, Kaoru, Ogura, Mizuki, Masunari, Taro, Tanaka, Masatsugu, Usuki, Kensuke, Ishikawa, Yuichi, Ando, Koji, Kondo, Yukio, Takagi, Yusuke, Takada, Satoru, Ishikawa, Maho, Choi, Ilseung, Sano, Akihiro, Nagai, Hirokazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123586/
https://www.ncbi.nlm.nih.gov/pubmed/37093243
http://dx.doi.org/10.1007/s00262-023-03432-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123586/
https://www.ncbi.nlm.nih.gov/pubmed/37093243
http://dx.doi.org/10.1007/s00262-023-03432-4

Ejemplares similares